Loperamide
- Generic Name
- Loperamide
- Brand Names
- Diamode, Imodium, Imodium Multi-symptom Relief
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33ClN2O2
- CAS Number
- 53179-11-6
- Unique Ingredient Identifier
- 6X9OC3H4II
- Background
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as diphenoxylate and haloperidol. Due to pharmacologic...
- Indication
Loperamide is indicated for the relief of diarrhea, including Travelers’ Diarrhea. As an off-label use, it is often used to manage chemotherapy-related diarrhea.
- Associated Conditions
- Diarrhea, Traveler's Diarrhea
- Associated Therapies
- -
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-06-03
- Target Recruit Count
- 80
- Registration Number
- NCT06424522
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 150
- Registration Number
- NCT05677282
- Locations
- 🇩🇯
Camp Lemonnier Djibouti, Djibouti, Djibouti
🇭🇳JTF-Bravo, Soto Cano AB, Comayagua, Honduras
🇰🇪British Army Training Site UK, Nanyuki, Kenya
Multi-System Analysis of Opioid Receptor Binding
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 60
- Registration Number
- NCT05528848
- Locations
- 🇺🇸
University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States
Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 50
- Registration Number
- NCT05520723
- Locations
- 🇪🇸
Hospital Universitario Donostia, San Sebastián, Donostia, Spain
🇪🇸Hospital Universitario General de Catalunya, Sant Cugat Del Vallès, Barcelona, Spain
🇪🇸Hospital Arnau de Vilanova, Lleida, Spain
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05252546
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 315
- Registration Number
- NCT05252988
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
🇪🇸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Prevention and Treatment of Pyrrolitinib-associated Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 470
- Registration Number
- NCT04736186
- Locations
- 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04366713
- Locations
- 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04315116
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT04225078
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.